Welcome to our dedicated page for Jin Medical SEC filings (Ticker: ZJYL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jin Medical International Ltd. (ZJYL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Jin Medical files annual reports on Form 20-F and furnishes interim updates on Form 6-K, which together present information on its operations in wheelchair manufacturing, rehabilitation medical equipment, living aids products and related health and beauty devices.
Through these filings, investors can review unaudited condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and details about the company’s manufacturing facilities in Changzhou, Taizhou and Chuzhou in China. Certain 6-K reports also describe material events, such as the launch of production at the Chuzhou intelligent manufacturing facility, appointment of independent directors and updates related to capital markets activities and registration statements on Form F-3.
Listing-related disclosures, including Nasdaq notifications about minimum bid price requirements and shareholder distribution rules, are typically reported via 6-K filings or referenced in company press releases. These documents help readers understand Jin Medical’s compliance status, potential remedial actions and associated timelines. Corporate governance information, such as committee assignments and director backgrounds, can also appear in these reports.
On Stock Titan, AI-powered tools summarize lengthy filings so users can quickly identify key points in Jin Medical’s 20-F and 6-K submissions, including segment information, risk discussions and updates on rehabilitation and assistive technology initiatives. Real-time integration with the SEC’s EDGAR system allows timely access to new filings, while structured views of exhibits and XBRL data support deeper analysis of financial and operational trends relevant to Jin Medical’s role in the surgical and medical instrument manufacturing sector.
Jin Medical International Ltd. director Franklin Oliver St Clair Jr filed an initial Form 3, which is a statement of beneficial ownership for insiders. This filing establishes his status as a director and provides a baseline ownership record, and it reports no transactions or trades in the company’s securities.
Jin Medical International Ltd. director TONG JAMES JIAYUAN has filed an initial Form 3, which identifies him as a director of the company. The filing data provided shows no reported share holdings or transactions, with all buy, sell, and exercise share counts listed as zero.
Jin Medical International Ltd. director Guo Yanru has filed an initial Form 3 as a reporting person for the company’s shares. The filing shows no reported share transactions, no derivative transactions, and no holding entries in this excerpt, effectively establishing a baseline for future insider ownership reports.
Jin Medical International Ltd. director and Chief Executive Officer Wang Erqi reported his beneficial ownership of the company’s ordinary shares. He beneficially owns 4,306,307 Class A Ordinary Shares through Jolly Harmony Enterprises Limited and Er Pu International Limited, and 1,000,000 Class B Ordinary Shares through Jolly Harmony Enterprises Limited, reflecting substantial indirect ownership and control over these holdings.
Jin Medical International Ltd. submitted an initial insider ownership report for Wang Ziqiang. The filing identifies him as both a director and the company’s Chief Financial Officer. The Form 3 does not report any insider share purchases, sales, or other transactions.
Jin Medical International Ltd. reports that it has regained compliance with Nasdaq’s minimum bid price requirement. The company’s Class A ordinary shares closed at or above $1.00 for thirteen consecutive business days from March 16, 2026 to April 1, 2026, satisfying Nasdaq Listing Rule 5550(a)(2).
To help address the prior deficiency, the board approved a 1-for-20 share consolidation effective March 16, 2026. After this consolidation, authorized capital is 45,000,000 Class A and 5,000,000 Class B ordinary shares, and 6,827,355 Class A and 1,000,000 Class B shares are issued and outstanding.
Jin Medical International Ltd. is implementing a 1-for-20 share combination of all authorized and issued Class A and Class B ordinary shares, effective with Nasdaq on March 16, 2026. This consolidation reduces issued Class A shares from 136,547,100 to 6,827,355 and Class B shares from 20,000,000 to 1,000,000.
The move follows shareholder approval at a January 30, 2026 extraordinary general meeting and coincides with a reclassification into dual Class A and Class B shares. The company explains that this action is part of a strategic plan to maintain compliance with Nasdaq continued listing requirements and to strengthen its long-term capital structure. Class A shares will keep trading under the symbol ZJYL on a consolidation-adjusted basis, with a new CUSIP G5140V120.
Jin Medical International Ltd., a Cayman Islands holding company, files its annual 20-F describing a business that designs and manufactures wheelchairs and living aids mainly for Japan and China through a China-based VIE structure. Public shareholders own the Cayman entity, not the PRC operating company.
The filing highlights structural and regulatory risks around the VIE contracts, potential PRC policy changes, cybersecurity and overseas listing rules, and the U.S. Holding Foreign Companies Accountable Act, while noting its auditors are currently subject to PCAOB inspections. Customer concentration is high: sales to Nissin and its subsidiaries were approximately 57.3%, 78.2% and 80.5% of revenue for fiscal 2025, 2024 and 2023.
The company also discloses restrictions on capital flows, foreign exchange and dividend payments from mainland China, and reliance on PRC subsidiaries and the VIE for cash generation. As of September 30, 2024, it reports cash of about $8.1 million, short-term investments of $18.6 million, total current assets of roughly $42.8 million and total current liabilities of about $17.2 million.
Jin Medical International Ltd. furnished a CEO fireside chat outlining its strategic priorities, capital plans, and manufacturing expansion. The CEO described a potential reverse stock split as both a Nasdaq compliance step and a broader “strategic reset” to realign the capital structure with long-term fundamentals and market perception.
Management highlighted three priorities: clearer, more frequent communication on strategic and operational milestones, disciplined capital allocation into manufacturing capacity, product certification and market expansion, and a long-term view that reflects medical-device regulatory cycles. Operating leverage is expected mainly from manufacturing efficiency, supply chain integration and product mix optimization.
The new Chuzhou factory, a 430,000 square foot facility in Anhui Province, is described as a cornerstone asset, targeting full-capacity production by the end of April 2026 to improve automation, quality control, cost per unit and global competitiveness. Jin Medical already runs two plants totaling about 230,000 square feet and sells over 30 wheelchair models through more than 40 distributors in China and over 20 internationally. The CEO also addressed industry growth drivers from aging populations and rehabilitation needs, and explained the company’s approach to US–China geopolitical risk via supply chain diversification, regional manufacturing flexibility and regulatory compliance. The company reiterated standard forward-looking statement cautions.
Jin Medical International Ltd. reported the results of its 2026 Extraordinary General Meeting of Shareholders. Shareholders holding 128,595,806.60 ordinary shares were present in person or by proxy, exceeding the quorum threshold out of 156,547,100 ordinary shares entitled to vote as of December 30, 2025.
Shareholders approved several special and ordinary resolutions, including adopting a second amended and restated memorandum and articles of association to create a dual class share capital structure. They also approved the 2026 Equity Incentive Plan, authorizing the board to issue up to 13,000,000 Class A ordinary shares as equity awards to directors, officers, employees, and other service providers.
Additional resolutions included authority related to matters contingent on the change of authorized share capital and authorization to adjourn the meeting if necessary. All resolutions received strong support, with votes for each proposal significantly exceeding votes against and abstentions.